FILE PHOTO: Bottles of medication sit on the shelf on the Rock Canyon Pharmacy, in Provo, Utah, U.S., Could 9, 2019. REUTERS/GEORGE FREY
(Reuters) – The Trump administration is interesting a court docket ruling that struck down its plan to compel pharmaceutical firms to reveal wholesale costs of their medication in televisions ads.
The Division of Well being and Human Providers (HHS) filed a discover of enchantment on Wednesday, because it prepares to problem the July federal court docket ruling.
“If the drug firms are embarrassed by their costs or afraid that the costs will scare sufferers away, they need to decrease them,” stated Caitlin Oakley, a spokeswoman for HHS.
In his ruling, U.S. District Decide Amit Mehta in Washington stated that HHS lacked the authority from U.S. Congress to compel drug producers to reveal listing costs.
The administration issued the rule in Could.
The rule, which utilized to medication with listing costs exceeding $35 for a one-month provide, is a part of a broader push by President Donald Trump to decrease drug costs.
HHS stated in July that it and the U.S. Meals and Drug Administration will suggest a rule that may permit it to authorize states and different teams to pursue pilot initiatives associated to importing medication from Canada.
Reuters has beforehand reported that the administration is contemplating broadening its plans to hyperlink the price of some medication for the federal government Medicare program to a global pricing index.
Reporting by Carl O’Donnell; Enhancing by Sonya Hepinstall